Aytu BioPharma Q4 revenue misses estimates

ReutersSep 23, 2025 8:15 PM

View all comments（0）



Overview

Aytu BioPharma fiscal 2025 revenue up 2% to $66.4 mln, misses Q4 estimates
Net loss narrows to $13.6 mln from $15.8 mln in fiscal 2024
EXXUA launch in fourth calendar quarter of 2025 expected to drive future growth

Outlook

Aytu to launch EXXUA in fourth calendar quarter of 2025
Company expects EXXUA to enter $22 bln US MDD market
Aytu anticipates EXXUA to drive significant growth in fiscal 2026

Result Drivers

ADHD REVENUE DECLINE - ADHD Portfolio revenue decreased slightly due to fewer prescriptions, offset by improved brand economics through Aytu RxConnect
PEDIATRIC GROWTH - Pediatric Portfolio revenue grew, driven by a return-to-growth plan that increased unit sales by 49%

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Miss	$15.14 mln	$17.90 mln (3 Analysts)
Q4 Net Income		-$19.82 mln
Q4 Adjusted EBITDA	Miss	$2 mln	$2.76 mln (3 Analysts)
Q4 Gross Profit		$10.25 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aytu Biopharma Inc is $9.00, about 72.3% above its September 22 closing price of $2.49

Press Release: ID:nACSvBp5ma

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

TradingKey - During the Asian trading session on May 11, SK Hynix shares rose by more than 15% at one point, hitting an all-time intraday high of 1.949 million KRW, with its market capitalization surpassing $900 billion. The year-to-date cumulative gain is approximately 197.03%, with the share price nearly tripling.

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

While there is still a risk of industry cycles, the current "Memory Crunch" has put Micron in a position of power that the company likely has never had in its 40-year history. For anyone looking to play the physical infrastructure of the future, MU stock is still a top pick for a diversified tech po

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

TradingKey - The U.S. Bureau of Labor Statistics will release the April CPI report on May 12 at 8:30 a.m. ET. Since the outbreak of the U.S.-Iran conflict in late February, the global energy market has experienced the most severe geopolitical supply shock in history. As the conflict enters its third month, traffic through the Strait of Hormuz remains significantly below pre-war levels, with approximately 20% of the world's oil transit routes still facing "interruption." This inflation report will serve as a critical validation window for the transmission effects of oil prices.

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

TradingKey — As the Nasdaq continues to hit consecutive record highs, Michael Burry—who rose to fame during the 2008 subprime mortgage crisis and was the inspiration for the film *The Big Short*—is betting with unprecedented intensity on the bursting of the AI bubble.

Featured Tools